CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

Atrial Fibrillation Clinical Trial

— CONNECT  

Official title:

CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00402246
• Other study ID #: 605
• Status: Completed
• Phase: N/A
• First received: November 17, 2006
• Last updated: February 23, 2011
• Start date: November 2006
• Est. completion date: September 2009

Study information

• Verified date: February 2011
• Source: Medtronic Cardiac Rhythm Disease Management
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the ability of clinicians to receive and review information from patients implanted with a heart device over the internet (remote care) is comparable to patients who are seen in-office for routine visits to check the status of their device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2009
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient will be implanted with a Medtronic Conexus-enabled Cardiac Resynchronization Therapy Defibrillator (CRT-D) or Implantable Cardioverter-Defibrillator (DR-ICD) device.

Exclusion Criteria:

• Patient has permanent rapid beats in the upper chamber of the heart (Atrial Fibrillation) - (constant atrial fibrillation in which pharmacological therapy or cardioversion failed or not attempted).

• Patient plans to be on chronic warfarin therapy post-implant and is no longer receiving therapies to attempt to control the rhythm of the beats in their atrium.

• Patient has a previous ICD, CRT-D, Implantable Pulse Generator (IPG) or Cardiac Resynchronization Therapy Pacemaker (CRT-P).

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Arrhythmia
• Atrial Fibrillation
• Tachycardia
• Ventricular Fibrillation

Intervention

Other:
• Remote Management
The Remote Management method of treating patients consists of 3 components: CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day) Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician. The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action.
• In-Office Care
Routine in-office care

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Medtronic Cardiac Rhythm Disease Management	Symbios Clinical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time Per Patient From a Clinical Event to a Clinical Decision in Response to Arrhythmias, Cardiovascular (CV) Disease Progression, and Device Issues	Days from device detection of a clinical event to a decision being made in response to the event, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event could be any of the following that satisfied pre-specified thresholds: arrhythmias (e.g. at least 12 hours of atrial tachycard/atrial fibrillation in a day), cardiovascular disease progression (e.g. multiple device shocks delivered to terminate a single episode), or device issues (e.g. low battery).	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	Health Care Utilization (HCU)	Count of HCU visits for each HCU type (cardiovascular (CV) hospitalizations, cardiovascular (CV) emergency department (ED), and cardiovascular (CV) unscheduled clinic office/urgent care visits)	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	Health Care Utilization: TEEs	Count of Transesophageal echocardiograms (TEEs) performed	Enrollment to last visit (up to 15 months post-implant)	No
Secondary	Actions Taken for HCU Visits	Count of HCU visits that involved specific actions taken	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	Clinically Meaningful Alerts	Count of clinically meaningful alerts as classified by the clinician	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	Symptomatic AT/AF Alerts	AT/AF represents atrial tachycardia or atrial fibrillation which are arrhythmias involving rapid beating of the atrial chambers of the heart. The devices in this study store how many hours each day that a patient experiences AT/AF. The patient may not be aware they are experiencing these atrial arrhythmias, but if the AT/AF is accompanied by symptoms, the AT/AF is said to be symptomatic AT/AF. Devices in this study have an alert that fires if the patient experiences at least a programmed amount of AT/AF in a day. Measure is count of symptomatic AT/AF alerts as classified by the clinician	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	AT/AF Alert Treatment	Count of the treatment (i.e. hospitalization, ED visit, unscheduled clinic office/urgent care visits) in response to the AT/AF alerts	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	Time Per Patient From a Clinical Event Onset to a Clinical Decision for Symptom-driven Device Interrogations	Days from a symptom-driven device interrogation event onset to a clinical decision being made in response to the event as reported by the clinician. An event is defined as a subject complaint received by the managing clinician in which the clinician determines that he/she must interrogate the subject's device to properly treat the subject.	Enrollment to last visit (up to 15 month post-implant)	No
Secondary	Time Per Patient From a Clinical Event Onset to a Clinical Decision for Both Device Events and Symptom-driven Device Interrogations	Days from device detection of a clinical event or a symptom-driven device interrogation event onset to a clinical decision, as reported by the clinician or as evidenced by device data obtained at interrogation. A clinical event is an event as defined in the primary objective. A symptom-driven device interrogation event is defined as a subject complaint received by the managing clinician in which the clinician determines that he/she must interrogate the subject's device to properly treat the subject.	From event onset to clinical decision	No
Secondary	CareLink Transmission Compliance	The CareLink Transmission Compliance Rate for a particular visit (e.g. 3 month visit) is the proportion (ranging from 0 to 1) of subjects with device interrogation data remotely transmitted via the CareLink system on the date it was scheduled to be sent for that visit. The proportion is a fraction in which the denominator is the number of subjects in the Remote Arm who were not exited from the trial prior to the visit of interest, and the numberator is the number of Remote Arm subjects who successfully transmitted device data via the CareLink system on the date it was scheduled to be sent.	3, 6, 9, 12 months visits	No
Secondary	Variability in Left Ventricular (LV) Threshold as Measured by Left Ventricular Capture Management (LVCM)	LV Capture Threshold is the required energy(volts) necessary to cause the left ventricule to contract. It is important that a device which paces the left ventricule be set to a threshold such that current conducted through the left ventricular lead will induce contraction in the left ventricle. However, these thresholds may vary over time.; The standard deviation and range (maximum LVCM threshold - minimum LVCM threshold) of the most recent 14 days of LVCM results prior to each follow-up visit were determined for each subject and used to assess within-patient variability in LV thresholds.	1, 3, 6, 9, 12, and 15 months visits	No
Secondary	State-Anxiety Scale	The State-Anxiety scales for each subject were obtained at multiple time points. The State-Anxiety scale was derived by summing the 20 scores in the State section of the State-Trait Anxiety Inventory (STAI) questionnaire. The State-Anxiety scales can vary from a minimum of 20 (best possible) to a maximum of 80 (worst possible).	1, 3, 6, 9, 12, and 15 month visit	No
Secondary	Trait-Anxiety Scale	The Trait-Anxiety scales for each subject were obtained at multiple time points. The Trait-Anxiety scale was derived by summing the 20 scores in the Trait section of the STAI questionnaire. The Trait-Anxiety scales can vary from a minimum of 20 (best possible) to a maximum of 80 (worst possible).	1, 3, 6, 9, 12, and 15 months visits	No
Secondary	Clinic Personnel Satisfaction With Wireless Telemetry (Telemetry + Leadless ECG).	Following the completion of enrollment in the study, participating clinicians were asked to complete a survey assessing their overall satisfaction with the wireless telemetry feature. Clinicians' rating (1=strongly disagree, 5=strongly agree) of the overall satisfaction with the wireless telemetry feature of the device	After study enrollment has been completed; on average 15.8 months after the center had enrolled its first subject	No
Secondary	In-office Follow-up Burden: Distance Traveled	Subjects' responses to the survey. Subjects were asked to provide the distance (in miles) from their home to the clinic/hospital.	1 month visit	No
Secondary	In-office Follow-up Burden: Patient Expenses	On a survey at the one month visit, the patient estimated their expenses in traveling to that visit.	1 month	No
Secondary	In-office Follow-up Burden: Hours Absent From Work Due to Visit	Subjects were asked at their one month visit to indicate on a survey how many hours of work they were missing to attend that visit.	1 month	No